Intermittent Fasting Attenuates Adriamycin-induced Hepatoxicity in Rats: Possible Role for Nrf2/HO-1 and LC3/Sirt1 Pathways
Reports of Biochemistry and Molecular Biology · 2025
DOI: 10.66224/rbmb.14.2.235 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reports of Biochemistry and Molecular Biology, 2025. Verfasst von Abdelaziz Mohamed Hussein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physiology, Faculty of Medicine, Mansoura University, Mansoura (35516), Egypt. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The current study was designed to examine, whether intermittent fasting can ameliorate the liver damage induced by adriamycin (ADR) in rats, as well as its possible underlying mechanisms.
Methods
Forty male Sprague Dawley rats were allocated into 4 equal groups, control, fasting, ADR and ADR+ Fasting groups. At the end of the experiment (eight weeks after ADR administration), blood samples were collected for the measurement of ALT, AST, and albumin, and liver tissues were harvested for biochemical analyses of oxidative stress markers (AMD, GSH and Catalase). Real-time PCR was performed for NRF2 and HO-1, as well as histopathological examination and immunostaining for caspase-3, LC3, and Sirt-1 expression.
Results
Administration of ADR caused significant elevation in liver enzymes (ALT, AST), lipid peroxidation (MDA), histopathological damage score and caspase-3 in liver tissues (p< 0.05) with a notable decrease in GSH, catalase, Nrf2, HO-1, LC3, and Sirt-1 genes expression (p< 0.05). Conversely, the application of intermittent fasting (IF) to ADR-treated rats caused significant attenuation of the raised liver enzymes (ALT, AST), lipid peroxidation (MDA), histopathological damage score and caspase-3 in liver tissues and significant improvement in the attenuated GSH, catalase, Nrf2, HO-1, Lc3 and Sirt-1 gene expression (p< 0.05).
Conclusion
Intermittent fasting could potentially offer protection against ADR-induced hepatotoxicity in rats by reducing oxidative stress and apoptosis and modifying the expression of Nrf2/HO-1, LC3, and Sirt-1.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Physiology, Faculty of Medicine, Mansoura University, Mansoura (35516), Egypt.
- Department of Medical Physiology, Faculty of Medicine, Al-Azhar University, Assiut, Egypt.
- Department of Internal Medicine, Faculty of Medicine, Delta University for Science and Technology, Mansoura (35516), Egypt.
- Department of Basic Sciences, Delta University for Science and Technology, Mansoura (35516), Egypt.
- Department of Medical Biochemistry, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia.
- Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, Riyadh, Saudi Arabia.
Zitieren
APA
Mohamed Hussein, A., Hamada Elsaid, F., El-Sayed, W., Abdelfatah Eid, E., Abd-Alhakem Ammar, O., Badway, A., Othman, G., & Elsaeed Mohammed Elmorshdy, S. (2025). Intermittent Fasting Attenuates Adriamycin-induced Hepatoxicity in Rats: Possible Role for Nrf2/HO-1 and LC3/Sirt1 Pathways. Reports of Biochemistry and Molecular Biology. https://doi.org/10.66224/rbmb.14.2.235
Vancouver
Mohamed Hussein A, Hamada Elsaid F, El-Sayed W, Abdelfatah Eid E, Abd-Alhakem Ammar O, Badway A, et al. Intermittent Fasting Attenuates Adriamycin-induced Hepatoxicity in Rats: Possible Role for Nrf2/HO-1 and LC3/Sirt1 Pathways. Reports of Biochemistry and Molecular Biology. 2025. doi:10.66224/rbmb.14.2.235
BibTeX
@article{MohamedHussein2025,
author = {Mohamed Hussein, Abdelaziz and Hamada Elsaid, Fathy and El-Sayed, Wessam and Abdelfatah Eid, Elsayed and Abd-Alhakem Ammar, Omar and Badway, Abdelnaser and Othman, Gamal and Elsaeed Mohammed Elmorshdy, Shorouk},
title = {Intermittent Fasting Attenuates Adriamycin-induced Hepatoxicity in Rats: Possible Role for Nrf2/HO-1 and LC3/Sirt1 Pathways},
journal = {Reports of Biochemistry and Molecular Biology},
year = {2025},
doi = {10.66224/rbmb.14.2.235}
}
EUVIMED